🇺🇸 FDA

Company profile · Sponsor

HALOZYME

HALOZYME THERAPEUTICS, INC.

HALO · NYSE biotech SAN DIEGO, CA, USA
Pipeline
24
Drugs
1
Patents
8

Quick answer

HALOZYME (HALO) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker HALO
Exchange NYSE
Company type biotech
Headquarters SAN DIEGO, CA, USA
SEC CIK 0001159036

Pipeline (24)

Search pipeline →

  1. Hylenex

    HALOZYME

    Pain

    phase 3 small molecule completed

    1 trial

  2. Placebo

    HALOZYME

    Pancreatic Ductal Carcinoma

    phase 3 small molecule terminated

    1 trial

  3. Testosterone enanthate

    HALOZYME

    Hypogonadism, Male

    phase 3 other active

    1 trial

  4. 5-Fluorouracil (5-FU)

    HALOZYME

    Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

    phase 2 small molecule completed

    1 trial

  5. Atezolizumab

    HALOZYME

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  6. Axumin PET/CT

    HALOZYME

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  7. CINRYZE with rHuPH20

    HALOZYME

    Hereditary Angioedema

    phase 2 mab completed

    1 trial

  8. Eribulin mesylate

    HALOZYME

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  9. Gemcitabine

    HALOZYME

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  10. Humalog

    HALOZYME

    Type 1 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  11. Humalog

    HALOZYME

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  12. Insulin lispro

    HALOZYME

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

  13. Insulin lispro

    HALOZYME

    Diabetes Mellitus, Type II

    phase 2 small molecule completed

    1 trial

  14. Mitomycin C

    HALOZYME

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  15. PEGPH20

    HALOZYME

    Metastatic Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  16. PEGPH20

    HALOZYME

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  17. PEGPH20

    HALOZYME

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  18. Pegvorhyaluronidase alfa

    HALOZYME

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  19. rHuPH20

    HALOZYME

    Dermatitis, Allergic Contact

    phase 2 small molecule completed

    1 trial

  20. Chemophase

    HALOZYME

    Superficial Bladder Cancer

    phase 1 small molecule completed

    1 trial

  21. Cohort 1: bococizumab 150 mg + rHuPH20

    HALOZYME

    Healthy

    phase 1 mab terminated

    1 trial

  22. Humalog

    HALOZYME

    Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  23. Insulin Lispro

    HALOZYME

    Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  24. Insulin aspart

    HALOZYME

    Type 1 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. hyaluronidase recombinant human

    HYLENEX RECOMBINANT

    INJECTION approved

Patents (8)

Search patents →

  1. US 12421308

    Anti-G-CSF antibodies and uses thereof

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12371685

    PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12264345

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12195773

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12178860

    Hyaluronidase enzyme formulations for high volume administration

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12152262

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12123035

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12110520

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is HALOZYME?

HALOZYME (HALO) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does HALOZYME sponsor?

We track 24 ClinicalTrials.gov-linked programs for HALOZYME, including Hylenex and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does HALOZYME company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.